Pigmentary Glaucoma
13
3
3
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.4%
2 terminated out of 13 trials
71.4%
-15.1% vs benchmark
8%
1 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (13)
Clinical Characteristics of Pigmentary Glaucoma and Efficacy Analysis of Ab-interno 120° Trabeculotomy
Topical Insulin for Glaucoma (TING2)
Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options
Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma
Safety and Effectiveness of the Hydrus Microstent
Autoimmune Dysregulation in Pigmentary Glaucoma
Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study
A Novel Argon Laser Iridoplasty for Pigment Dispersion Syndrome
IOP and Medication Reduction in MIGS Procedures
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes
Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube
IOP Fluctuations in Patients With Primary Open-angle Glaucoma, Before and After Selective Laser Trabeculoplasty